Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine patients who meet IHS criteria for migraine with or without aura of both sexes~* 18-70 years~* 45-95 kg.~Exclusion Criteria:~* Any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week)~* Serious somatic or psychiatric disease~* Pregnancy~* Intake of daily medication (except oral contraceptives)~* Triptan non-responders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: ACTIVE_COMPARATOR): headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
- Placebo (Type: PLACEBO_COMPARATOR): headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb

Based on this trial design, predict the completion outcome and termination type (if applicable).